Harvard Bioscience (HBIO) Other Non-Current Liabilities (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Other Non-Current Liabilities of $1.1 million for Q1 2026, down 19.07% year-over-year from $1.4 million in Q1 2025, and down 12.39% quarter-over-quarter from $1.3 million in Q4 2025.
Harvard Bioscience (HBIO) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Other Non-Current Liabilities for 17 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 19.07% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 19.07% YoY), while the FY2025 annual figure was $1.3 million, up 4.22% from the prior year.
- Other Non-Current Liabilities declined to $1.1 million in Q1 2026 per HBIO's latest filing, from $1.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.6 million in Q2 2024 and bottomed at $418000.0 in Q2 2022.
- Historically, Other Non-Current Liabilities has averaged $1.2 million across 5 years, with a median of $1.3 million in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 83.53% — and 2023, when it jumped 150.24%.
- Harvard Bioscience's Other Non-Current Liabilities stood at $1.0 million in 2022, then surged by 46.72% to $1.5 million in 2023, then decreased by 14.97% to $1.3 million in 2024, then grew by 4.22% to $1.3 million in 2025, then slipped by 12.39% to $1.1 million in 2026.
- Business Quant data shows HBIO's Other Non-Current Liabilities at $1.1 million in Q1 2026, $1.3 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 892,000.00 |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 418,000.00 |
| Mar 31, 2022 | 598,000.00 |
| Dec 31, 2021 | 486,000.00 |
| Sep 30, 2021 | 2.47 Mn |